Afficher la couverture 'Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group | Spanjaart, Anne Mea' en grand format
/5

0 avis

Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group

Archive ouverte

Spanjaart, Anne Mea | Ljungman, Per | de La Camara, Rafael | Tridello, Gloria | Ortiz-Maldonado, Valentín | Urbano-Ispizua, Alvaro | Barba, Pere | Kwon, Mi | Caballero, Dolores | Sesques, Pierre | Bachy, Emmanuel | Di Blasi, Roberta | Thieblemont, Catherine | Calkoen, Friso | Mutsaers, Pim | Maertens, Johan | Giannoni, Livia | Nicholson, Emma | Collin, Matthew | Vaz, Carlos Pinho | Metafuni, Elisabetta | Martinez-Lopez, Joaquin | Dignan, Fiona | Ribera, Josep-Maria | Nagler, Arnon | Folber, Frantisek | Sanderson, Robin | Bloor, Adrian | Ciceri, Fabio | Knelange, Nina | Ayuk, Francis | Kroger, Nicolaus | Kersten, Marie José | Mielke, Stephan

Edité par CCSD ; Springer Nature -

International audience

Consulter en ligne

Suggestions

Du même auteur

Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group

Archive ouverte | Spanjaart, Anne Mea | CCSD

International audience. Abstract COVID-19 has been associated with high mortality in patients treated with Chimeric Antigen Receptor (CAR) T-cell therapy for hematologic malignancies. Here, we investigated whether t...

Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

Archive ouverte | Rejeski, Kai | CCSD

International audience. Hematological toxicity is the most common adverse event after chimeric antigen receptor (CAR) T-cell therapy. Cytopenias can be profound and long-lasting and can predispose for severe infecti...

Monitoring multidimensional aspects of quality of life after cancer immunotherapy: protocol for the international multicentre, observational QUALITOP cohort study

Archive ouverte | Vinke, Petra | CCSD

International audience. Introduction Immunotherapies, such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy, have significantly improved the clinical outcomes of various malignancies. How...

Chargement des enrichissements...